{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 14 of 51', 'Study ID RCB: 2020-A00652-37', 'baseline. The therapeutic objective achievement is defined as \"satisfied\" or \"very', 'satisfied\" response on 4 points Likert scale.', '-', 'Level of concordance between the satisfaction level in regard to the therapeutic', 'objective set by the PSO-TARGET QoL Component grid and the DLQI at the 2nd follow-up', 'visit (52 4 weeks.).', '- Research of predictive factors (among baseline characteristics) of the achievement of the', 'main treatment goal.', '-', 'Percentage of agreement between the physician-reported and the patient-reported', 'dimensions at the first follow-up visit.', '-', 'Rate of patients having changed objective at the 1st follow-up visit (12/ 16 weeks).', '-', 'Percentage of patients who have maintained at 52 + 4 weeks the level of satisfaction', 'achieved at the 1st follow-up visit.', '-', 'PASI Scores at baseline, at the 1st follow-up visit (12/ 16 weeks), at the 2nd follow-up visit', '(52 + 4 weeks.).', '-', 'Level of accordance between PASI 90/100 and the satisfaction level in regard to the', 'therapeutic objective set by the PSO-TARGET QoL Component grid.', '-', 'DLQI Scores at baseline, at the 1st follow-up visit (12/ 16 weeks), at the 2nd follow-up visit', '52 + 4 weeks.', 'Data sources', \"Patients' data will be collected at day 0, at the 1st follow-up visit (12/16weeks) and at the\", \"2nd follow-up visit at 52 4 weeks according to the physician's practice.\", 'As a prospective study, the following data will be collected during the patient visit:', 'disease history, concomitant treatments, previous anti psoriatic treatment and adverse events.', 'In addition, the following study specific data will be collected: disease severity (PASI score),', 'quality of life questionnaires (DLQI, PSO-TARGET component grid).', 'Study size', 'The main criterion is the sensitivity of the PSO-TARGET tool (percentage of patients who', 'consider their target objective as being achieved after 12/16 weeks of treatment as defined', 'by a \"satisfied or very satisfied\" response, assessed on a 4 points Likert scale, among patients', 'with a DLQI total score of 0 or 1).', 'The sample size calculation is based on the following hypotheses', ':', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 15 of 51', 'Study ID RCB: 2020-A00652-37', 'Sensitivity : 90%', 'Absolute precision : 10%', 'Type I error : 5%', 'Power at 80%', 'Prevalence: 80% (estimated rate of patients with a DLQI 0-1 after 12 weeks of', 'treatment.', 'Based on these hypotheses, the sample size needed is estimated at 134 evaluable patients.', 'Assuming 10% of patients will not be evaluable on main criterion, 150 patients have to be', 'included.', 'Data analysis', 'Analysis of the primary endpoint', 'The performance of the PSO-TARGET QoL component grid to assess the treatment impact on', \"the patients' quality of life will be determined by calculating the sensitivity and specificity of\", 'the grid compared to the DLQI (reference). The grid will be validated if both the specificity and', 'sensitivity parameters reach the 85% threshold.', 'Milestones', 'Regulatory Submissions: Q2 2020', 'Start of data collection Q3 2020', 'End of data collection Q2 2022', 'Final report Q4 2022', '5', 'Amendments and Updates', 'None', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 16 of 51', 'Study ID RCB: 2020-A00652-37', '6', 'Milestones', 'Planned dates for study milestones are indicated in the table below:', 'Milestone', 'Planned Date', 'Start of data collection', 'Q3 2020', 'End of data collection', 'Q2 2022', 'Final study report', 'Q4 2022', 'The start of the study is defined as the date on which the first information on a study patient', 'is recorded in the study dataset. LEO will ensure that End-of-Data Collection (End of Study)', 'notification is submitted to the concerned authorities and IECs for each site, for each country', 'and for the complete study.', 'Based on upcoming knowledge, LEO might choose to terminate the study prematurely. In such', 'case the Committee(s), study sites, IECs and authorities will be informed promptly.', '7', 'Rationale and Background', 'Psoriasis is a chronic, immune-mediated inflammatory skin disease. Clinical manifestations of', 'psoriasis can be of multiple forms, including, among others, plaque psoriasis, guttate psoriasis,', 'palmoplantar psoriasis, and pustular psoriasis (Lebwohl, 2018). Psoriasis is characterized by an', 'abnormal keratinocyte proliferation in the interfollicular epidermis along with an infiltration', 'of antigen-presenting cells and release of pro inflammatory cytokines, leading to a local', 'inflammation (ppagunta et al., 2016; Lowes et al., 2007). The aetiology of the disease is not', 'fully understood, but a number of risk factors are recognized, including family history and', 'environmental risk factors, such as smoking, stress, obesity, and alcohol consumption (Huerta', 'et al., 2007). The prevalence of psoriasis is difficult to evaluate with precision but is estimated', 'around 2-4% in western countries (Gelfand et al., 2005; Kurd and Gelfand, 2009; Stern et al.,', '2004). In France, the prevalence of psoriasis is estimated to 4,4 % (Richard et al., 2018).', \"Psoriasis causes considerable psychosocial disability and has a major impact on patients'\", 'quality of life (Krueger et al., 2001).', 'The severity of psoriasis can be influenced by a great variety of factors including extent of the', 'disease, inflammation, lesions location and impact on quality of life. As those factors can', \"fluctuate over time, so can the intensity of the disease and more importantly the patient's\", 'perception of his/her affliction. The current standard of care for treatment of psoriasis is', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']", "completion": ""}